Blaze Bioscience

Blaze Bioscience is a clinical-stage biotech developing targeted imaging agents to illuminate cancer cells during surgery. Its lead candidate, tozuleristide (BLZ-100), is an investigational product designed to help surgeons achieve complete tumor resection by providing real-time, direct visualization of malignant tissue. Founded in 2010 and built on technology from the Fred Hutchinson Cancer Research Center, the company is targeting significant unmet needs in surgical oncology, starting with brain and breast cancers. Blaze remains privately held and is led by a management team with extensive experience in biotech development, finance, and clinical operations.

Tumor Paint® platform: fluorescent peptide-dye conjugates (e.g., tozuleristide/BLZ-100) that bind to cancer cells and fluoresce under near-infrared light, paired with the CANVAS® imaging system for real-time intraoperative visualization of tumor margins.

Blaze competes in the intraoperative imaging market with companies developing contrast agents (e.g., Avelas Biosciences' AVB-620) and imaging systems (e.g., Stryker's SPY-PHI, Zeiss' INFRARED 800). Its chlorotoxin-based agent differentiates it through a unique tumor-targeting mechanism. Broader competition includes advanced MRI, ultrasound, and pathology techniques used for margin assessment.